George Magrath Acquires 90,294 Shares of Opus Genetics, Inc. (NASDAQ:IRD) Stock

Opus Genetics, Inc. (NASDAQ:IRD) CEO George Magrath purchased 90,294 shares of Opus Genetics stock in a transaction on Friday, November 15th. The stock was bought at an average price of $1.01 per share, with a total value of $91,196.94. Following the transaction, the chief executive officer now owns 483,244 shares of the company’s stock, valued at approximately $488,076.44. This represents a 22.98 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

George Magrath also recently made the following trade(s):

• On Monday, November 18th, George Magrath purchased 9,706 shares of Opus Genetics stock. The shares were purchased at an average cost of $1.02 per share, for a total transaction of $9,900.12.

Opus Genetics Stock Down 3.0 %

Opus Genetics stock traded down $0.03 during mid-day trading on Tuesday, reaching $0.88. 243,421 shares of the company’s stock traded hands, compared to its average volume of 173,666. Opus Genetics, Inc. has a 12-month low of $0.85 and a 12-month high of $3.40.

Opus Genetics (NASDAQ:IRD) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.01. The firm had revenue of $3.87 million during the quarter, compared to the consensus estimate of $1.17 million. Opus Genetics had a negative net margin of 324.45% and a negative return on equity of 63.65%. Equities research analysts expect that Opus Genetics, Inc. will post -1.22 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright started coverage on shares of Opus Genetics in a report on Wednesday, November 13th. They issued a “buy” rating and a $8.00 target price on the stock.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.